Lapatinib Plus Letrozole May Improve Efficacy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 2
Volume 18
Issue 2

In metastatic breast cancer (MBC), lapatinib (Tykerb) + letrozole (Femara) delayed disease progression in HER2+, HR+ patients, according to initial results from a phase III trial (EGF30008) presented by Stephen Johnston, MD (abstract 46).

In metastatic breast cancer (MBC), lapatinib (Tykerb) + letrozole (Femara) delayed disease progression in HER2+, HR+ patients, according to initial results from a phase III trial (EGF30008) presented by Stephen Johnston, MD (abstract 46).

EGF30008 is testing whether combined endocrine and targeted HER2 inhibition improves outcomes in HR+ MBC. Crosstalk between the EGFR and steroid receptor pathways has been implicated in endocrine resistance in breast cancer. For HR+ patients receiving AIs, adding a drug that targets both EGFR and HER2 pathways may enhance endocrine responsiveness, Dr. Johnson said. “This study suggests that combining an AI with the orally active dual TKI lapatinib may be a better approach.”

Patients (N = 1,286) received letrozole ± lapatinib as first-line treatment. In the cohort with HR+, HER2+ disease (n = 219), lapatinib/letrozole significantly increased median PFS from 3.0 mo with letrozole alone to 8.2 mo, for a 29% reduction in risk of progression (P = .019). Response rates were significantly increased (15% to 28%) and clinical benefit was observed in 29% and 48%, respectively; OS is premature, but a nonsignificant 26% reduction in risk was seen with the combination.

In the entire population (irrespective of HER2 status), there was less effect with the combination, though the 1-mo increase in PFS (11.9 vs 10.8 mo) was statistically significant (P = .026). In HER2- patients, median PFS was ~ 13.5 mo in both arms; no additional benefit was seen with lapatinib. When HER2- patients were stratified by endocrine sensitivity, endocrine-resistant patients (relapse < 6 mo post-tamoxifen) had improvement in PFS from 3.1 mo with letrozole to 8.3 mo with both agents: a 22% nonsignificant risk reduction. For endocrine- sensitive patients, median PFS was ~ 15 mo in each arm. Dr. Johnston called these findings intriguing but cautioned that at this point they are exploratory only.
 

Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
Related Content